• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

IGC Pharma, Inc. Common Stock (NY:IGC)

0.2000 +0.0110 (+5.82%)
Official Closing Price Updated: 8:00 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 615,171
Open 0.1910
Bid (Size) 0.1889 (400)
Ask (Size) 0.2039 (200)
Prev. Close 0.1890
Today's Range 0.1806 - 0.2019
52wk Range 0.0800 - 0.4041
Shares Outstanding 49,784,017
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
IGC Pharma's Alzheimer's Agitation Drug Candidate Now Patented in the U.S., Canada, and Mexico as Phase 2 Readout Nears
November 05, 2026
Canada grants patent on IGC-AD1, an investigational oral therapy for agitation in Alzheimer's disease. Agitation is one of the hardest symptoms for families to manage. 
From IGC Pharma, Inc.
Via ACCESS Newswire
News headline image
5 Biotech Stocks’ TCRT, IGC, PDSB, PFAI, Acquisition, Alzheimer’s, Cardio and Cancer Research Milestones
October 13, 2026
Via AB Newswire
Topics Artificial Intelligence

Performance

52-Week Range 50.5% below 52-week high
0.2000
0.0852W Low 0.4052W High
1 Week 0.9% below 1-week high
0.181W Low 0.201W High

IGC Pharma, Inc. Common Stock (IGC) traded between $0.08 and $0.40 over the past 52 weeks and last traded at $0.20, 50.5% below its 52-week high. Over the past week it ranged between $0.18 and $0.20.

Past 12 Months
+3.7%
-29.8%
-25.2%
-34.0%
-31.3%
-45.6%
1W +$0.01
1M -$0.08
3M -$0.07
6M -$0.10
YTD -$0.09
1Y -$0.17

IGC was -45.6% over the past year, -34.0% over six months, -31.3% year to date, +3.7% in the last week.

12 Months vs Market
IGC
-45.6%
DIA
+9.0%
SPY
+9.6%
QQQ
+7.6%
IWM
+13.3%

Over the past 12 months IGC returned -45.6% versus DIA (Dow) +9.0%, SPY (S&P 500) +9.6%, QQQ (Nasdaq 100) +7.6% and IWM (Russell 2000) +13.3%.

Volume & Liquidity 0.80× 3-mo avg
Today 615,171 3-mo avg 766.5K
1W
500.8K
1M
530.9K
3M
766.5K
6M
651.6K
YTD
744.7K
1Y
743.7K

IGC most recently traded 615,171 shares against a 3-month average daily volume of 766.5K.

More News

Read More
News headline image
IGC Pharma Unveils PRISM AI Platform to Move Alzheimer's Risk Prediction to Brain-Health Action and Commercial Deployment
October 13, 2026
From IGC Pharma, Inc.
Via ACCESS Newswire
News headline image
4 Low-Priced Listed Stocks: VIVS, IGC, RIME, TOPP, With Catalysts to Watch
October 07, 2026
Via AB Newswire
Topics Animal Testing Artificial Intelligence
News headline image
2026 Biotech Watchlist IBRX, PACB, IGC, VIVS Lead 7 Stocks in Focus
October 01, 2026
Via AB Newswire
News headline image
2026 Nanocap Stocks to Watch: IGC, KNRX, GYGY, ARAY Lead Watchlist Now See More Inside!
September 28, 2026
Via AB Newswire
Topics Artificial Intelligence
News headline image
VivoSim Labs Inc. (NASDAQ: VIVS) Targets the Multibillion-Dollar Cost of Failed Drugs
September 28, 2026
Via AB Newswire
News headline image
IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026
September 28, 2026
From IGC Pharma, Inc.
Via ACCESS Newswire
News headline image
Greenland Stocks in Focus: GLND, GRML, CRML Lead the Watchlist More Names Inside
September 21, 2026
Via AB Newswire
Topics Government
News headline image
VivoSim Labs Inc. (NASDAQ: VIVS) Takes Aim at Pharma’s 92% Drug-Failure Problem
September 21, 2026
Via AB Newswire
Topics Animal Testing
News headline image
PullBack Stocks PDSB, PRSO, IGC, RETO: Who Breaks First?
September 15, 2026
Via AB Newswire
Topics Artificial Intelligence
News headline image
IGC Pharma (NYSE: IGC) Target Raised on Alzheimer’s 2027 Outlook
September 01, 2026
Via AB Newswire
Topics Artificial Intelligence
News headline image
Nasdaq 30’s VIVS, IGC, RIME, AIXI Stocks Now
August 26, 2026
Via AB Newswire
Topics Artificial Intelligence
News headline image
MicroCaps IGC, BIVI, ORBS, RIME Sub-$1 Stocks to Watch Now
August 20, 2026
Via AB Newswire
Topics Artificial Intelligence
News headline image
VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum
August 17, 2026
Via AB Newswire
Topics Animal Testing Artificial Intelligence
News headline image
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure
August 17, 2026
From IGC Pharma, Inc.
Via ACCESS Newswire
News headline image
Microcaps TOON, IGC, SURG, MDXH to Watch Now as Earnings, AI and Biotech Catalysts Build
August 14, 2026
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
News headline image
VivoSim Labs (NASDAQ: VIVS) Emerges in Drug Toxicity Market as Revenue Growth Guidance Tops 500% – Plus More In Focus
August 14, 2026
Via AB Newswire
Topics Animal Testing Artificial Intelligence
News headline image
Kartoon Studios (NYSE: TOON) Enters Next Growth Phase; Reports Q2 Revenue of $5.82M, EPS of $0.38 and $40.5M Cash Position – Plus More in Focus
August 14, 2026
Via AB Newswire
Topics Intellectual Property
News headline image
Kartoon Studios (NYSE: TOON) Signs Amazon Prime Deal for “Hundred Acre Wood” Streaming Launch
August 13, 2026
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
News headline image
Early Alert: PLAG, PRSO, UZX, IGC Lead Sub-$1 Stocks to Watch – Plus More in Focus
August 11, 2026
Via AB Newswire
Topics Artificial Intelligence
News headline image
IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout
August 11, 2026
From IGC Pharma, Inc.
Via ACCESS Newswire
News headline image
New to The Street Show 766 Broadcasts Tonight at 6:30 PM ET on Bloomberg Television, Featuring BioVie's Bezisterim Parkinson's Disease Clinical Results
August 08, 2026
From New to The Street
Via ACCESS Newswire
News headline image
Bullish Volume: RITR, IGC, BJDX, CISS Lead Active Sub-$1 Stocks to Watch
August 05, 2026
Via AB Newswire
Topics Artificial Intelligence Economy Fraud
News headline image
Microcaps MGRX, PRSO, IGC, KUST In the News to Watch
July 31, 2026
Via AB Newswire
Topics Artificial Intelligence Energy Fraud

Frequently Asked Questions

Is IGC Pharma, Inc. Common Stock publicly traded?
Yes, IGC Pharma, Inc. Common Stock is publicly traded.
What exchange does IGC Pharma, Inc. Common Stock trade on?
IGC Pharma, Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for IGC Pharma, Inc. Common Stock?
The ticker symbol for IGC Pharma, Inc. Common Stock is IGC on the New York Stock Exchange
What is the current price of IGC Pharma, Inc. Common Stock?
The current price of IGC Pharma, Inc. Common Stock is 0.2000
When was IGC Pharma, Inc. Common Stock last traded?
The last trade of IGC Pharma, Inc. Common Stock was at 11/06/26 08:00 PM ET
What is the market capitalization of IGC Pharma, Inc. Common Stock?
The market capitalization of IGC Pharma, Inc. Common Stock is 9.96M
How many shares of IGC Pharma, Inc. Common Stock are outstanding?
IGC Pharma, Inc. Common Stock has 10M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap